A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms MAGNIFY
- Sponsors Celgene Corporation
- 04 Jun 2019 Interim results (n=270) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 15 May 2019 According to a Celgene Corporation media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting.
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History